Publications

Showing 6 of 6 Publications

2017

Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.
Fisher G, Pommier R, Wolin E, Kunz P, Liyanage N, Pitman Lowenthal S, Mirakhur B, Shaheen M, Vinik A. Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. Journal Of Clinical Oncology 2017, 35: 4088-4088. DOI: 10.1200/jco.2017.35.15_suppl.4088.
Peer-Reviewed Original Research
Concepts

2016

438P Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study
Wolin E, Fisher G, Kunz P, Liyanage N, Lowenthal S, Mirakhur B, Pommier R, Shaheen M, Vinik A. 438P Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study. Annals Of Oncology 2016, 27: vi143. DOI: 10.1093/annonc/mdw369.23.
Peer-Reviewed Original Research
Concepts
440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study
Fisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. 440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study. Annals Of Oncology 2016, 27: vi144. DOI: 10.1093/annonc/mdw369.25.
Peer-Reviewed Original Research
Concepts
Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster Award
Fisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster Award. The American Journal Of Gastroenterology 2016, 111: s457-s458. DOI: 10.14309/00000434-201610001-01052.
Peer-Reviewed Original Research
Concepts
Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study
Wolin E, Fisher G, Kunz P, Liyanage N, Lowenthal S, Mirakhur B, Pommier R, Shaheen M, Vinik A. Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study. The American Journal Of Gastroenterology 2016, 111: s468. DOI: 10.14309/00000434-201610001-01076.
Peer-Reviewed Original Research
Concepts

2015

Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy
Fisher G, Wolin E, Kunz P, Liyanage N, Gomez-Panzani E, Lowenthal S, Pommier R, Shaheen M, Vinik A. Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy. The American Journal Of Gastroenterology 2015, 110: s1007. DOI: 10.14309/00000434-201510001-02424.
Peer-Reviewed Original Research
Concepts

Download Full List